Aerpio Pharmaceuticals Announces Uplisting to Nasdaq Capital Market and Pricing of $45.0 Million Public Offering of Common Stock
Puma Biotechnology Announces Results of CHMP Reexamination of MAA for Neratinib for Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer
Arcus Biosciences and Infinity Pharmaceuticals Announce Clinical Collaboration to Evaluate Lead Programs in Triple-Combination Studies
VersaBank Subsidiary VersaVault Beta Testing Phase One of its Blockchain Based Vault Initiative to Securely Store Digital Property
Agios and CStone Pharmaceuticals Announce Exclusive Collaboration and License Agreement to Develop and Commercialize Ivosidenib in Greater China
ZEMDRITM (plazomicin) Approved by FDA for the Treatment of Adults with Complicated Urinary Tract Infections
Alliance Reports Positive Results in Chronic Pain Relief from the Leading-Edge Proprietary CBD DANA Hemp Strain
Kivalliq Announces Timing of Shares Trading on a Consolidated Basis and Name Change to ValOre Metals Corp. (TSX-V:VO)
Signature Resources Announces Closing of First Tranche of Private Placement and Lingside Claims Purchase
MGX Minerals Announces Closing of Oversubscribed $15.5M Private Placement for Lithium and Advanced Material Projects
Silver Viper Enters Into Definitive Agreements to Acquire Rubi-Esperanza Claims, La Virginia Gold-Silver Project, Sonora, Mexico
Khiron Appoints Internationally Recognized Medical Cannabis Specialist Dr. Maria Fernanda Arboleda as Medical Director
Boehringer Ingelheim and Lilly announce positive top-line Phase III data results for empagliflozin as adjunct to insulin in type 1 diabetes
European Commission Grants Marketing Authorization for Gilead’s Biktarvy for the Treatment of HIV-1 Infection
Pfizer Announces Overall Survival Results from Phase 3 PALOMA-3 Trial of IBRANCE in HR+, HER2- Metastatic Breast Cancer
FDA Accepts Supplemental Biologics License Application for Merck’s KEYTRUDA as Adjuvant Therapy in Advanced Melanoma
La Jolla Pharmaceutical Company Announces European Medicines Agency Validation of Marketing Authorisation Application for GIAPREZA
BioCryst Reports Agreement with PMDA on Phase 3 Clinical Trial and Regulatory Requirements for Marketing Authorization of BCX7353 in Japan